Exact Sciences (EXAS) News Today

Exact Sciences Corporation (NASDAQ:EXAS) News Summary

Investors are weighing a mix of analyst moves, corporate developments and market reactions that are influencing EXAS shares today.

• Positive Sentiment: Cathie Wood’s ARK Investment Management increased its position in Exact Sciences, reflecting confidence from a leading growth-oriented fund. Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock
• Positive Sentiment: An analyst highlighted that Q2’s $0.01 EPS loss was far smaller than the $0.19 consensus miss and praised the exclusive Freenome licensing deal as a long-term growth driver. Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
• Positive Sentiment: Zacks upgraded EXAS to a #1 (Strong Buy), signaling growing optimism around the company’s earnings trajectory. Exact Sciences (EXAS) Upgraded to Strong Buy
• Positive Sentiment: Exact Sciences signed an exclusive licensing agreement with Freenome, potentially expanding its cancer-screening portfolio. Exact Sciences signs exclusive deal with biotech firm Freenome
• Positive Sentiment: Analysts at Evercore ISI maintained an “outperform” rating and set a $64 price target, implying over 50% upside.
• Positive Sentiment: A recent analysis suggests EXAS may reach breakeven soon, underlining improving operational leverage. Breakeven On The Horizon For Exact Sciences Corporation
• Neutral Sentiment: Barclays trimmed its price target to $55 while keeping an “overweight” stance, balancing valuation concerns with growth potential. Exact Sciences (NASDAQ:EXAS) Price Target Cut to $55.00 by Analysts at Barclays
• Neutral Sentiment: The full Q2 2025 earnings call transcript is now available for investors to review management’s commentary. Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: EXAS updated its FY2025 revenue outlook to $3.1–$3.2 billion vs. consensus $3.1 billion, while EPS guidance was not detailed.
• Neutral Sentiment: Trading was briefly halted due to a LULD pause, a reminder of the stock’s recent volatility.
• Neutral Sentiment: The company is investing $775 million to expand its cancer-screening capabilities, underscoring its focus on market leadership. How Exact Sciences Is Spending $775 Million To Dominate The Cancer-Screening Market
• Negative Sentiment: UBS cut its price target from $61 to $53 and moved to a “neutral” rating, reflecting caution on near-term growth. Exact Sciences (NASDAQ:EXAS) Given New $53.00 Price Target at UBS Group
• Negative Sentiment: Royal Bank of Canada lowered its target to $46 and kept a “sector perform” rating amid long-term uncertainty. Royal Bank Of Canada Has Lowered Expectations for Exact Sciences (NASDAQ:EXAS) Stock Price
• Negative Sentiment: Shares hit a new 12-month low after the latest round of analyst downgrades. Exact Sciences (NASDAQ:EXAS) Hits New 12-Month Low After Analyst Downgrade
• Negative Sentiment: Shares plunged despite a Q2 beat, underscoring investor skittishness over profitability timelines. Exact Sciences shares plunge despite earnings beat
• Negative Sentiment: Market commentary labels EXAS’s new licensing deal as “throwing good money after bad,” highlighting skepticism about short-term returns. Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
• Negative Sentiment: After reporting strong Q2 results, EXAS stock still fell over 15%, reflecting investor concerns about execution and cash burn. Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%